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1 – Introduction 
Many have claimed that a revolution has occurred in medi-
cine since the post-genomics era arose around 2000. Several 
names have been used to refer to this revolution: ‘Person-
alized medicine’ (Langreth and Waldholz 1999), ‘precision 
medicine’ (National Research Council [US] Committee on 
A Framework for Developing a New Taxonomy of Disease 
2011), ‘stratified medicine’ (Food and Drug Administration 
2014), ‘P4 medicine’(Hood and Friend 2011), and, less nota-
bly, ‘individualized medicine’ (Fischer and al. 2015)  and ‘P5 
medicine’ (Pravettoni and Gorini 2011; Khoury and al. 2012). 
Apart from ‘personalized’, which was the first to appear, ad-
jectives are sometimes proposed to  justify a definition that 
contrasts what this medicine ‘truly’ is with what a previously 
proposed term (most often ‘personalized’) would ‘wrongly’ 
suggest it is. Sometimes, the goal is to differentiate one in-
novative medicine from another. Moreover, each attempts to 
emphasize a different property of this (or these) new medi-
cine(s). Table 1 provides some examples of the terminological 
confusion in the scientific literature. It differs from the best 
descriptive analysis of the occurrences of these names that I 
could find (Pokorska-Bocci et al. 2014). 
Philosophers have tried to order this obvious conceptual 
mess (see Schleidgen et al. 2013 for an example). Indeed, it 
is tempting for a philosopher to analyze the difference be-
tween these names and their definitions so as to produce a 
conceptual map of meanings of some sort (Pokorska-Bocci 
et al. 2014). However, there are important limits to such an 
analysis.
 
First, sticking to the discussion of terms and their definitions 
is likely to either miss important aspects of the underlying re-
alities or to mix the actual with the potential. For instance, in 
the review by Pokorska-Bocci et al. previously referred to, the 
exclusion criterion was precisely that no paper mentioning 
“specific therapy for specific condition” should be retained, 
but only papers discussing “general concepts” (Pokors-
ka-Bocci et al. 2014).
Second, it is safe to assume that these terms mostly refer to 
the same enterprise in all its ramifications, and are thereby in 
competition, each of them having some rightful claim to be 
the most appropriate. Deciding is taking a side, if implicitly, 
which raises the question of a philosopher’s (or sociologist’s 
or historian’s) motives. For instance, philosophers Green and 
Vogt describe in silico modeling as a recent medical devel-
opment that fits well into personalized medicine under the 
form of P4 medicine; but one may reasonably ask why not 
precision or stratified medicine instead (Green and Vogt 
2016)? The same sort of problem appears in many other con-
tributions (Schleidgen et al. 2013; Boenink 2010; Fleck 2010; 
Bragazzi 2013), but few focus on the question of terms (see 
for instance Juengst et al. 2016) or approach it as a question 
to be negotiated among stakeholders (De Grandis and Hal-
gunset 2016). For this reason, I will refer to all these terms 
collectively as ‘p-medicine’, so as not to decide whether it 
should be called ‘personalized’, ‘precision’, ‘predictive’, ‘par-
ticipatory’, ‘individualized’, ‘stratified’, or anything else.
Third, each of these names refers to aspects of specific tech-
nologies or procedures, which it is also more or less arbitrary 
to emphasize for conceptual reasons. Arguments to decide 
which is the proper name or which is the central technology,  
Despite its vagueness, ‘Personalized’, ‘Precision’, ‘P4’, ‘P5’, ‘individualized’, ‘strat-
ified medicine’—or p-medicine in short—has become an increasingly popular term 
in biomedical literature. Philosophers have attempted to analyze what these various 
terms involve and have discussed consequences for medical practices. In this article, 
I address a different, but crucial question:  what has made this project of p-medicine 
convincing to so many? My argument is that without real achievements, it would not 
have been the case. I also make the case that these achievements stem from the 
domain of monoclonal antibodies (mab), a new type of drug that prompted talks of 
personalized, precise, stratified, etc., medicine. In conclusion, while it may be possible 
to label any projection in the future of medicine as ‘p-medicine’, it is impossible to 
overlook mab-medicine as the spearhead of current research programs in p-medicine 
and medical practices that follow.
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Personalized
Genetic base for highly specific drugs: 
tailor-made drugs that will treat people 
based on their individual genetic makeup 
(Langreth and Waldholz 1999)
Molecular base for highly specific treat-
ments: Application of genomic and mole-
cular data to better target the delivery of 
healthcare, facilitate the discovery and 
clinical testing of new products, and help 
determine a person’s predisposition to 
a particular disease or condition (Abra-
hams, Ginsburg, and Silver 2005)
Precision
Molecular base for accurate taxonomy: 
Integration of molecular research with 
clinical data from individual patients to 
develop a more accurate molecular taxo-
nomy of diseases to enhance diagnosis 
and treatment and tailor disease mana-
gement (National Research Council [US] 
Committee on A Framework for Develo-
ping a New Taxonomy of Disease 2011)
Stratified
Statistical use of biomarkers to match 
treatments: Matching therapies with 
specific patient population characteris-
tics using clinical biomarkers (Trusheim, 
Berndt, and Douglas 2007) Fischer et al. 
uses ‘individualized’ in the same sense 
(Fischer et al. 2015)
Individualized
Cell therapy: “Therapies involving pa-
tient’s own cells in diseases where there is 
no efficient drug treatment available, e.g., 
stem cell therapies and cancer vaccines” 
(cited in Pokorska-Bocci et al. 2014)
P4
Networking big data to represent indi-
vidual well-being within predictive, per-
sonalized, preventive and participatory 
models: “actionable understandings of 
disease and wellness as a continuum of 
network states unique in time and space 
to each individual human being” (Hood 
and Flores 2012)
P5
P4+psychocognitive: “psychocognitive 
aspects to be considered in order to em-
power the patient” (Pravettoni and Gorini 
2011)
P4+ population perspective: “A popula-
tion perspective integrates predictive me-
dicine into the ecologic model of health; 
applies principles of population screening 
to preventive medicine; uses evidence-
based practice to personalize medicine; 
and grounds participatory medicine on 
the three core functions of public health: 
assessment, policy development, and as-
surance.” (Khoury et al. 2012)
Table 1. A sample of general definitions of p-medi-
cine in the literature. 
however, are necessarily weak since p-medicine often refers 
to potential rather than to actual procedures, so much so that 
there is an important futurological aspect to the choice of the 
name (Hedgecoe 2005; Tutton 2012). Evidence can be found 
in the proportion of editorials that refer to ‘p-medicine’ as 
compared to original research papers (see figure 1). Further-
more, scientific—along with marketing, political and episte-
mological—motives complicate the choice of a label. Under 
such constraints, explaining the evolution of language (see 
figure 2 and 3) invokes serious sociological, historical and 
philosophical questions.
For these reasons, it is impossible to answer such questions 
as: ‘what is properly speaking p-medicine?’ and ‘how should 
it be properly called?’, based on verbal or programmatic defi-
nitions. P-medicine is whatever one likes it to be, granted 
that we are 1) talking about new, but heterogeneous medi-
cal procedures and technologies, and 2) mostly referring to 
their future achievements. De Grandis and Halgunset’s have 
already made this point and they insisted that context of use, 
ethical concerns and politics should also be taken into con-
sideration in a negotiation over the meaning of the word (De 
Grandis and Halgunset 2016). This paper follows a different 
path. I suggest that a systematic, critical review of the actual 
achievements and current technologies and procedures un-
dergirding talks of p-medicine can provide the adequate basis 
of a descriptive definition, rather than a normative one.
Such an enterprise has not really been undertaken yet. It is 
the only approach that may clarify why precisely these words 
have been chosen with some persuasive force. In this paper, 
the methodological assumption is that actual achievements 
of ‘p-medicine’ are what really matters in the justification of 
any label, because only they justify so much discussion about 
such a project. The contention breaks down into two claims:
 
1) p-medicine is, strictly speaking, nothing but an ens ra-
tionis created by the legitimate desire to discuss the future 
consequences of medical innovation – as such everybody 
can define it as they like, there is no true or false defini-
tion, and most of those proposed are relevant, more or 
less depending on what you find is and is not interesting, 
or bet will change medicine (a claim close to De Grandis 
and Halgunset 2016).
2) however, there also are real achievements underneath 
so much ado. They make p-medicine an enterprise to be 
taken seriously not only for what may be projected, but 
mostly for what has already been achieved. Most of these 
achievements fall under the development of monoclonal 
antibodies (mabs). A less conceptual, but more adequate, 
description of the effective and current part of p-medicine 
would therefore be mab-medicine.
These two claims are indeed distinct. Moreover, it is predicta-
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ble that most readers, 
as philosophers, may 
agree with [1], but 
will probably feel un-
comfortable with [2], 
which sounds more 
surprising.
The following inquiry 
proceeds as follows. 
Section 2 lists five 
technologies that po-
tentially define 
p-medicine, name-
ly: the massive use 
of biomarkers, sys-
tems biology, inno-
vative treatments, 
big data process-
ing, and a new 
paradigm of care. 
Section 3 sets mo-
lecularization and 
computerization of 
diseases as the two 
pillars on which 
p-medicine rests. 
Section 4 details the considerable development of this spe-
cific sort of drugs, monoclonal antibodies, as the spearhead 
of the p-medicine revolution. Section 5 defines them as the 
original paradigm of p-medicine. Section 6 concludes with 
some methodological clarifications that may prevent the 
reader from fully accepting this view of what personalized / 
precision / stratified medicine really is.
2 – The boy who lived: technol-
ogies and interpretations de-
fining p-medicine
Let us start with an oft-cited example of p-medicine to illus-
trate what p-medicine consists in. It is considered the first 
successful application of whole-exome sequencing. The sem-
inal paper detailing this case, which has about 500 citations 
on Google Scholar, was published in Genetics in Medicine in 
2011 and describes an undiagnosed 15 month old child with 
symptoms similar to those of severe Crohn disease. An ex-
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ome sequencing led to the identification of 16,124 genetic var-
iants, within which further analysis selected a mutation in the 
X-linked inhibitor of apoptosis (XIAP) gene, that is, a unique 
case of a previously unobserved Mendelian disease. The boy 
was successfully treated by an allogeneic hematopoietic pro-
genitor cell transplant (Worthey et al. 2011). Note that other 
similar cases of individually tailored treatments have been 
both widely cited in professional literature and published in 
the general press (see for instance Mnookin 2014).1
Before examining the various interpretations that have been 
proposed, let us make two important caveats. First, this ex-
ample is not typical of the revolution of p-medicine for three 
reasons: cases of individually-tailored therapies in p-medi-
cine are much rarer than in other technologies; resorting to 
cell transplantation is equally rare; and, this form of Inflam-
matory Bowel Disease is unique. Yet it is paradigmatic in so 
far as it involves ‘precision’, is molecular, genomic, personal-
ized, computerized, and preventative: the very terms found in 
typical definitions of what p-medicine consists in. Second, it 
is not exactly true that whatever made this treatment possible 
is a decisively new technology. Treating one boy, treating him 
in a very precise manner, treating him preventively, etc., has 
not become possible all of a sudden. On the contrary, all this 
has been possible for years, even decades. More generally, 
medicine, it has often been noted, has not suddenly become 
personal, precise, predictive, stratified, etc., but has been so 
for a long time. Rather, with p-medicine, medicine is (or is 
becoming) more personal, more stratified, more precise, 
more predictive, etc. Furthermore, this progress is not just 
a gradual improvement, but thought of as a significant accel-
eration. P-medicine is supposed to be a revolution because it 
has been making medicine a great deal more personal, pre-
cise, predictive, etc.
That said, I suggested an analysis focused on the technolo-
gies that make such cases possible. Five sets of technologies, 
I propose, have been said to have brought these fundamen-
tal changes to medicine. The papers referred to above men-
tioned them all, and only they were mentioned in all of them.
1) The use of biomarkers. A biomarker, or a biologi-
cal marker, is a molecule significantly associated with 
health-related states, that can be detected and measured 
(Biomarkers Definitions Working Group. 2001; Strimbu 
and Tavel 2010). Examples are: blood levels of X, genetic 
polymorphisms, the exome of a tumor, etc. In the boy’s 
case, the key biomarker is one SNP, that is a tag for a spe-
cific mutated gene called XIAP, which was never observed 
before in association with Crohn’s disease. For the past 
two decades, biomarkers have been intensely investigated 
and increasingly used in clinical practice for diagnostic, 
therapeutic and prognostic purposes. In comparison to 
labels such as ‘precision medicine’, which hits a total re-
cord of 10,000 papers on pubmed, the entry ‘biomarker’ 
returns ca. 800,000 papers as of Sept. 1st, 2016. The trend 
looks to be more a constant accumulation rather than an 
acceleration. An already old list of biomarkers of interest 
can be found in Barh, Blum, and Madigan (2011, p. 348). 
2) Theorizing in the framework of systems biology. Basic 
biomedical science is shifting from traditional ‘box and 
arrow’ models to more complex models required by the 
flood of data now available, mainly through –omics. In 
the boy’s case, the performed exome sequencing resulted 
in 16,124 variants as compared to the human reference 
sequence. A selection had to be done according to various 
criteria. For instance, as the disorder was not known, the 
first hypothesis was that this mutation would also be un-
known, which reduced the number of potential variants 
to 1,527, of which only 879 would result in a different 
amino-acid. One of the most important selection criteria 
is Polyphen, “a tool that predicts the impact of an amino 
acid substitution on the structure and function of a hu-
man protein” (Worthey et al. 2011). This software reduced 
the number very significantly so that, in the end, by way 
of a priori reasoning, only one mutation is left. Polyphen, 
developed by Harvard University (Adzhubei et al. 2010), 
calculates the probability that a mutation is deleterious, 
based on methods typical of systems biology. More gener-
ally, many mathematical and methodological innovation 
are increasingly investigated and resorted to in research, 
as well as in practice. A key paper concerning the intro-
duction of systems biology into medical science is Ideker, 
Galitski, and Hood’s (2001) while Barabási, Gulbahce, 
and Loscalzo’s (2011) concerns the introduction of ‘net-
work medicine’.
3) Using conceptually innovative treatments.  Innova-
tive treatments that have appeared within the last two 
decades clearly seem to utilize significantly different mol-
ecules. It is not so much the number of new molecules on 
the market, as it is the number of innovative treatments. 
In the boy’s case, it is a cell transplant from the moth-
er. Cell transplant is part of p-medicine’s arsenal, but not 
the most resorted to. There is, for instance, a tendency 
to repurpose already existing drugs, yet, nonetheless, sig-
nificantly new molecules have entered the market, either 
resulting from ‘drug design’ (as imatinib and other tyros-
ine kinase inhibitors [TKI]), or from advanced biological 
engineering (as trastuzumab and other monoclonal anti-
bodies [mabs]). 
4) Big Data: Computer-assisted research and treatment. 
New data of many kinds can now be collected, stored, cat-
egorized, or crunched into decisions. In the specific do-
main of oncology, Vice-President Joe Biden launched the 
Cancer Moonshot Initiative in 2011, a project creating a 
shared platform of biological data relevant to cancer. In 
the boy’s case, big data computer technology made a full 
1 - Example brought to my attention by Kathryn Tabb.
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exome sequencing, a comparison with highly conserved 
SNPs in non-diseased humans, and a comparison with 
all previously known mutations of the gene called XIAP. 
More generally, numerous platforms have been devel-
oped to collect traditional medical records, results of 
whole genome sequencing, metagenomic and transcrip-
tomic data, in humans as well as in animal models, and 
even data from wearable devices (see Canuel et al. 2015 
for a review of the main platforms).
5) A new paradigm of care. P-medicine seems to involve 
a shift in the practices of medical care. The acknowledg-
ment section in the original paper reporting the boy’s case 
testifies to the unusual number of people who cooperat-
ed in his care (Worthey et al. 2011).  Doctor-patient re-
lationships, decision processes, patient networking, but 
also health policies (including regulation of drug approv-
al), have all undergone significant changes in relation to 
p-medicine.
Altough all these technologies were involved in this case, 
different interpretations of what is going on can be given. 
Each expectedly emphasizes different technologies and im-
plements them into a different strategy. To comprehensively 
situate interpretations of p-medicine strategy, I researched 
each general paper concerning this boy’s procedure that has 
been cited over 100 times. This allowed me to reconstitute 
three different narratives of what exactly is the p-medicine 
that saved this ‘XIAP’ boy’s life. These narratives are of-
ten proposed at different places in the same paper or even 
meshed together.
1) An individual boy with a unique condition may be saved 
because powerful, accurate and trustworthy devices are 
available in the clinics.
This view is championed by an FDA report published in 2014. 
‘P-medicine’ still is ‘personalized medicine’ to the FDA. As a 
regulator, i.e., not a researcher, a pharmaceutical company, 
a policy-maker, a patient, a health practitioner, etc., the FDA 
insists on the medical products that allow for the detection 
and processing of biomarkers on the one hand, and the treat-
ment of the condition on the other hand:
“Personalized medicine generally involves the use of two 
medical products – typically, a diagnostic device and a 
therapeutic product – to improve patient outcomes. A 
diagnostic device is a type of medical device. Diagnostic 
devices include both in vitro tests such as assays used in 
measurement of genetic factors and in vivo tests, such 
as electroencephalography (EEG), electrocardiography 
(EKG), or diagnostic imaging equipment.” (Food and 
Drug Administration 2014) 
Only such products can support the grand ambition of
 
“the tailoring of medical treatment to the individual char-
acteristics, needs and preferences of a patient during all 
stages of care, including prevention, diagnosis, treatment 
and follow-up.” (Food and Drug Administration 2014) 
This general interpretation, which focuses on the idea that 
available devices work, appears is most frequently in the 
literature regarding this particular case. Being no longer 
reserved for researchers, many credit the broadened use of 
genomic platforms with saving the boy’s life (see for exam-
ple Chan and Ginsburg 2011; Soon, Hariharan, and Snyder 
2013); others, however, insist on the availability of the shared 
infrastructure to compare data on a large scale (Manolio et 
al. 2013).
2) The ability to bypass traditional disease entities and use 
genomic database to target the relevant biomarker, identify 
the involved biological network and imagine a potentially 
efficient treatment: this is what saved this boy’s life.
The National Research Council endorses the corresponding 
general view in a 2011 report. They played a role in the shift 
from ‘personalized’ to ‘precision’ in p-medicine:
“as used in this report, “precision medicine” refers to the 
tailoring of medical treatment to the individual charac-
teristics of each patient. It does not literally mean the 
creation of drugs or medical devices that are unique to a 
patient, but rather the ability to classify individuals into 
subpopulations that differ in their susceptibility to a par-
ticular disease, in the biology and/or prognosis of those 
diseases they may develop, or in their response to a spe-
cific treatment.” (National Research Council (US) Com-
mittee on A Framework for Developing a New Taxonomy 
of Disease 2011)
P-medicine generally consists in linking biomarkers to treat-
ments through innovative means, mainly, huge shared repos-
itories where data is organized according to a new taxonomy, 
instead of observed clinical signs and traditional disease en-
tities. This general view supports a second tendency in the 
interpretation of the XIAP boy’s case: to emphasize the ‘diag-
nosis’ of a new – even potentially unique – condition, thanks 
to (mainly genomic) biomarkers (see examples in Fan, Han, 
and Liu 2014; McCarthy, McLeod, and Ginsburg 2013; Li and 
Meyre 2014).
3) The ability to generate many hypotheses and then reduce 
the number to the only one to fit the data for this individual, 
this is what saved this boy.
This view is for instance that of the advocates of ‘P4 Medi-
cine’. They consider that 1) –omics data is treated through 
2) systems medicine models which provides 3) stratification, 
which makes possible 4) personalized care (which is also 5) 
participatory, 6) predictive and 7) preventive). The critical 
component is the computer power capable of reducing data 
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dimensionality to simple hypotheses.
“The convergence of patient-activated social networks, 
big data and their analytics, and systems medicine has led 
to a P4 medicine that is predictive, preventive, personal-
ized, and participatory. (…) For example, in 10 years each 
patient will be surrounded by a virtual cloud of billions of 
data points, and we will have the tools to reduce this enor-
mous data dimensionality into simple hypotheses about 
how to optimize wellness and avoid disease for each indi-
vidual.” (Hood 2013)
 
The XIAP boy’s case has also been interpreted as an exam-
ple of network analysis enabled by bioinformatics platforms 
(Gamulin 2016), the difficulty being to “process terabytes of 
information” (Kahn 2011) or “decipher the information that 
is locked in a patient’s genome” (Katsanis and Katsanis 2013)
While competitive, these three narratives, infrastructure, 
-omics approach, algorithm, are not incompatible with each 
other. Emphasizing different aspects of p-medicine, they in-
terpret differently the way technologies are organized or how 
they fit together in a plan for action. Moreover, there may be 
many other interpretations. Instead of focusing on the inter-
pretations, which may vary, the rest of the paper focuses on 
the technologies, which do not, and hypothesizes that the lat-
ter matter more than the former. This is not to say that inter-
pretations are not important in how p-medicine is conceived 
and implemented, but that it matters less in how it should 
be defined, than which technologies are involved exactly, and 
what they actually achieve.
 
3 – Molecularization and com-
puterization are the two pillars 
of p-medicine
Whence came the idea that some of these technologies just 
described above would converge towards precision, person-
alization and stratification? What did explain the rise of this 
program of p-medicine?
Many think it started with genome sequencing because ge-
nomes make us individuals. Yet, the human genome project, 
which did not describe ‘the’ human genome, or even ‘a’ hu-
man genome, but a mean human genome (based on vari-
ants most commonly found in several anonymous donors), 
remained prohibitively expensive to apply on an individual 
basis. Only recently has it become an affordable and sustain-
able project for the whole of medicine. Noteworthily, the fun-
damental reason genomics alone cannot produce anything 
akin to p-medicine is that the obtained data is incomparable 
with any standard of a whole genome and can only be applied 
piecemeal, on a gene-gene basis. Most of it would thereby not 
be interpretable for a long time (and still is not). What made 
p-medicine possible, was molecularization through the study 
of the genome, and computerization for storing and manip-
ulating such data for comparison. All the references above, 
without any exception, mention these two technologies at 
least, although they do not all mention others such as sys-
tems biology, or innovative healthcare, or innovative treat-
ments. In this view, p-medicine would essentially consist in 
an agenda of molecularization and computerization of indi-
vidual genomes. Indeed, neither the complex models of sys-
tems biology, nor big data biology, would have been possible 
without molecularization and computerization: they together 
constitute the infrastructure on which p-medicine could be 
built (on molecularization, see Chadarevian and Kamminga 
(2003); Boniolo and Nathan (2016); on computerization, see 
Stevens (2013)). However, it is still a long shot from molecu-
larization and computerization of biology to personalized or 
stratified medicine.
In the list given above, the third technology to have played 
a role is not likely to be the change in the paradigm of care. 
Indeed, it has been advocated, with some reason, that mo-
lecularization changes our very concept of a person (Guchet 
2016, pp. 22, 26, 32). Yet it surely is compatible with our tra-
ditional concepts of what a person is, nor does it challenge it 
more than the discovery of localized brain functions in the 
XIXth century.
The list of technologies given above suggests that innovative 
treatments may have played a significant role in the interpre-
tation of these technologies as a unified program of p-medi-
cine. Interestingly, let us imagine what more than a decade of 
talks of p-medicine would have sounded like, were there no 
innovative treatments to support them. Storing, comparing, 
characterizing genomes, exomes or transcriptomes is only 
a descriptive task: by no means does it make it medicine as 
there are no treatments, tailored or not. Molecularization 
and computerization provide advances in the understanding 
of how diseases work, but it could have been the case that it 
does not come with advances in treatments. However, less 
than a decade before the Human Genome Project, ‘tailored’ 
treatments had been developed under different categories, 
such as gene therapy and antibodies. As a matter of fact, 
only with personalized, precision or stratified effective treat-
ments, could personalized, precision or stratified medicine 
be possible or, at least, convincing as a realistic agenda for 
medicine. A recent opinion article in The New England Jour-
nal of Medicine concluded that “[l]earning more about the 
variability of the molecular characteristics of individual tu-
mors and its relationship to the natural history and outcome 
of disease is important research but has not facilitated choice 
of treatment” (Tannock and Hickman 2016). How could such 
fundamental research be properly called p-medicine? In the 
rest of the present paper, I suggest that the particular suc-
cess of a new kind of treatments, monoclonal antibodies, has 
greatly helped the acceptance of molecular and computerized 
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medicine as p-medicine. 
Drug repurposing Chemical
Muscle atrophy Ursolic acid
Lung cancer Cimetidine (a antiulcer 
drug)
Hepatocellular carcinoma 
(HCC) 
Chlorpromazine and trifluo-
perazine
Hair growth Fluphenazine (an antipsy-
chotic drug)
Osteoarthritic pain Phenoxybenzamine (an 
anti-hypertensive drug) 
Inflammatory bowel disease Topiramate (an anticonvul-
sant drug) 
Breast cancer (tamoxifen-
resistant)
Phenothiazines (antipsy-
chotic and antihistaminic 
drugs)
Lung cancer Polyphyllin D (a potent 
cytotoxic saponin) 
Gastric cancer Vorinostat (for cutaneous T 
cell lymphoma) 
CNS injury Piperazine (antipsychotic 
drug)
Table 2. Applications of the connectivity map project 
to drug repurposing in 2012 (after Qu and Rajpal 
2012)
mab TKI
Number of studies/open studies1 3562/1026 535/183
Number of phase 1 studies/open 
phase 1 studies2
1329/427 177/69
Number of phase 2 studies/open 
phase 2 studies2
1845/507 303/107
Number of phase 3 studies/open 
phase 3 studies2
583/155 63/22
Number of phase 4 studies/open 
phase 4 studies2
111/40 9/3
Number of conditions2 848 307
Number of rare diseases2 232 84
Number of sponsors/collabora-
tors (industry)2
138 62
Number of molecules with FDA 
approval3
66 39
Number of molecules under deve-
lopment
Table 4. Relative importance of Monoclonal Anti-
bodies (mabs) and tyrosine kinase inhibitors (TKI) 
in clinical studies.
Therapeutic 
area
Drug Biomarker
Oncology
Arsenic Trioxide
PML/RARa
Tretinoin
Brentuximab 
Vedotin
CD30
Capecitabine
DPD
Fluorouracil
Cetuximab EGFR
Panitumumab
Crizotinib ALK
Denileukin Difi-
titox
CD25/IL2
Exemestane
ER/PR
Fulvestrant
Letrozole
Imatinib
C-Kit, PDGFR, 
FIP1L1
Lapatinib
HER2
Pertuzumab
Trastuzumab
Everolimus
Nilotinib
Ph ChromsomeDasatinib
Imatanib
Rasburicase G6PD
Tositumomab CD20 antigen
Vemurafenib BRAF
Psychiatry
Citalopram CYP2C19
Valproic acid UCD
Psychiatry, 
Neurology
Pimozide
CYP2D6
Aripiprazole
Iloperidone
Trabenazine
Thioridazine
Pulmonary Ivacaftor CFTR
Analgesics Celecoxib CYP2C9
Antivirals Maraviroc CCR5
Hematology Lenalidomide
Chromosome 5q 
deletion
Table 3. Drugs involving specific criteria for stratifi-
cation or repurposing (after Food and Drug Admin-
istration 2014, pp. 37-8)
2 - Source: ClinicalTrials.gov (August 2016)
3 - Source: fda.gov
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4 – Monoclonal antibodies are 
the spearhead of p-medicine
The only way for p-medicine to be convincing enough as a 
therapeutic project is to draw from successful treatments, 
specific enough to be contrasted to traditional treatments in 
terms of ‘personalization’ (or precision or …), the possibility 
of a generalization to a sufficiently broad spectrum of diseas-
es. First, it has to be successful treatment: just more accu-
rate diagnosis or prognosis, would not properly be called a 
revolution in medicine in the end. Second, these treatments 
cannot simply be more efficient only since—comparable to 
traditional treatment—this would not fail to adequately jus-
tify a new label. Third, they cannot be limited in principle to 
a narrow range of pathological conditions, but must contain 
open possibilities. However efficient and personalized (or 
precise, or…) an innovative treatment for cancer might be, 
if it was in principle limited to cancer cells, it would not be 
called p-medicine, but p-oncology at best.
Although persuasive arguments may show more than one 
sort of innovative treatment has met these three conditions, 
clearly monoclonal antibodies do. First, some of them were 
dramatically more effective than standard treatments. Sec-
ond, as antibodies target proteins, there is practically no limit
to the potential effects of manipulated antibodies in an organ-
ism. Third, they have several specific features, such as: selec-
tive efficiency on stratified population; much less severe side 
effects in general; greater design; and less serendipity during 
development, which, in turn, lowers development cost. These 
are the features p-medicine is a generalization of. Now the 
rest of this section is dedicated to showing that monoclonal 
antibodies have a prominent position in contemporary treat-
ments associated to p-medicine. The following section will 
focus on their specific features.
In general, 3 categories of innovative technologies have been 
involved in p-medicine: drug repurposing, stratification, and 
development of new drugs. Drug repurposing involves broad-
ening the spectrum of action of a prescription drug to include 
a previously excluded population (see table 2 for examples 
and for a glimpse of the real scale of recent achievements by 
such practices). Stratification involves restricting the pre-
scription of a drug to a fraction of a population that suffers 
from the same diagnosed condition. Both technologies may 
be needed simultaneously in some cases. A criterion is need-
ed for both technologies: it is either a molecular, specific 
biomarker, or a more or less complex pattern of signs, the 
recognition of which involves big data processing, or both. 
Biomarkers and big data are the only innovations involved 
in drug repurposing and stratification. Yet the development 
of these innovative technologies is small compared to the 
development of new drugs, many of which also involve bio-
markers, stratification and big data processing. If repurpos-
ing and stratification obviously play a role in p-medicine, it is 
reasonable to focus on their use in the development of these 
new drugs. Indeed, as resorted to for traditional molecules, 
they remain marginal.
Table 3 shows 34 drugs with a biomarker that serves for 
“guidance”. Note first that guidance is not “prescription”. Cit-
alopram, for instance, is a widely used antidepressant drug, 
generally prescribed without any biological test for the bio-
marker. Note also that if 5 treatments only were originally 
approved before 1998, many more are not properly “innova-
tive”. 14 of them are either tyrosine kinase inhibitors (TKI) or 
monoclonal antibodies, which makes it 15 innovative treat-
ments, if one includes Ivacaftor as the FDA suggests.
To this list of innovative treatments, one should add fusion 
proteins (of which few are not mabs), cell therapy, gene ther-
apy and immunotherapy (cytokines, lymphokines, imiqui-
mod, and the targeted inhibition of PD-1 by mabs).
From a historical perspective, the first category of innova-
tive drugs is TKI. Gleevec has been called a targeted drug 
as opposed to antimitotic drugs, long before the terms ‘per-
sonalized’ or ‘precision’ medicine were used in the current 
sense. It is not inappropriate, however, to call TKI a part of 
the p-medicine arsenal. Note that TKI ranksecond to mab in 
numerical importance in clinical research. The numbers of 
approved molecules are in a proportion of 3:2, but the num-
ber of studies, open studies for any phase, are in a proportion 
comprised between 5:1 and 10:1 (see table 4). An important 
part of the explanation is that the domain of application of 
TKI is almost entirely restricted to cancer therapy (with very 
few exceptions). On the other hand, mab can be used in al-
most all conditions. The FDA study established the propor-
tions of “activities” involved in “personalized medicine” in 
2012 as 33 % in oncology, 21% in cardiorenal medicine, 11% 
in neurology, 7% in both antiviral medicine and pulmonary 
medicine, 5% in psychiatry, and the remainder in other areas 
(Food and Drug Administration 2014, p. 55).
This brief overview of the field suggests that if one were to 
remove mabs, TKI, stem cell and immunotherapy would fail 
to justify wide acceptance of p-medicine outside of oncology. 
Only mabs are efficient, specific and ubiquitous enough for 
the concept of p-medicine to have emerged as a convincing 
description of successful technologies that may be general-
ized. However, this does not imply that only mabs qualify as 
instances of p-medicine. But it contends that they constitute 
the main, representative and archetypic, treatment of p-med-
icine. An investigation of their specific features could there-
fore be used as a benchmark for any general description of 
how p-medicine should be defined.
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5 – Mabs as archetypes for p 
-medicine
A comparison of mabs’ main properties with p-medicine’s 
offers some evidence of overlap, suggesting that the latter 
has indeed been inspired by the former. First, trastuzumab 
(Herceptin) is the most commonly cited example of p-medi-
cine success. Second, all five practices described in section 2 
are typically used in either the development, prescription or 
understanding of mabs. Trastuzumab is to be prescribed af-
ter testing for a biomarker, a cell receptor called ‘HER/neu’, 
which leads to stratification. Only up to a third of patients 
with breast cancer benefit from this treatment, most patients 
with breast cancer do not at all, and some patients with other 
forms and locations of cancer may also benefit from trastu-
zumab. Side effects are dramatically less severe and/or less 
likely to occur than with usual cancer treatments. Third, only 
mabs provide at the same time more personalization, stratifi-
cation and precision in a credible bid to generalize the project 
to the whole of medical practice. Indeed, most of the develop-
ment of biomarkers and of the practice of stratification, has 
actually come with mabs. Just to cite the example of multi-
ple sclerosis, natalizumab is the most resorted to, but also 
alemtuzumab, rituximab, ocrelizumab, taclizumab are used 
in clinical practice. They also have much rarer side effects. 
Some of them are devoted for very specific uses, others, like 
natalizumab, are efficient in almost all individuals without 
significant side effects. Table 5 provides an idea of the devel-
opment of biomarkers in the case of this condition.
The prominence of mabs in the field of p-medicine is not 
just an accidental fact. An explanation of the situation may 
indeed be found in molecular properties of mabs as opposed 
to other drugs. First of all, they are ‘biologics’, and mimic a 
natural class of proteins, antibodies, that have a significantly 
more specific binding behavior than traditional molecules. 
They also are metabolized in a different way that produces no 
active metabolites and makes them much less likely to elicit 
side effects. Most certainly they do have side effects, just as 
all treatments, but these are much more manageable and ob-
viously less severe in many domains, especially in oncology, 
but also in neurology or rheumatology. mabs’ important mo-
lecular mass explains both properties.
Moreover, they are produced with technologies of rational 
drug design rather than discovered serendipitously through 
screening. This is not unique to mabs, as it is also the case 
with TKI, even though the expression ‘rational drug design’ 
should not be taken too literally, which is emphasized by 
Keating and Cambrosio (2014). The difference lies in the 
much broader field of potential variations and applications 
of antibodies. Whereas targeted therapies as TKI focus on an 
enzyme that come to have a very specific activity in patholog-
ical processes as opposed to healthy mechanisms, mabs may 
in principle act upon every macromolecule in an organism.
Established biomarkers Diagno-
sis
Pro-
gnosis
Treat-
ment 
res-
ponse/
side 
effects
Cerebral spinal fluid-specific 
oligoclonal bands
+ (+) -
Intrathecal immunoglobulin 
production
+ (+) -
Intrathecal anti-viral immu-
noglobulin production
+ - -
Magnetic resonance imaging + (+) (+)
Neutralizing antibodies 
against beta-interferon  
- - (+)
Neutralizing antibodies 
against natalizumab 
- - +
Antibodies against JC virus - - +
Aquaporin 4 antibodies + (+) (+)
Potential biomarkers
CD56 bright natural killer 
cells
- - (+)
Cytokines/chemokines - - (+)
Myelin oligodendrocyte 
glycoprotein antibodies 
(+) - -
Intrathecal/oligoclonal 
immunoglobulin M produc-
tion
- (+) -
Transcriptomics - - (+)
Genetics (+) (+) (+)
Table 5. Summary of established and potential bio-
markers for diagnosis, prognosis, and treatment of 
multiple sclerosis (in Derfuss 2012). ‘+’ means that 
it is used in clinical practice, ‘(+)’ that more clinical 
data is needed and ‘-’ that there is no clear evidence.
 
The question is not whether a specific antibody exists, which 
acts on target such and such, but rather, how to design a 
monoclonal antibody which will. Let us imagine that the 
whole class of TKI and the whole class of mabs have been de-
veloped and tested. Given what we now know, nobody would 
expect the class of TKI to cure many other pathological con-
ditions apart from cancers, whereas many would expect one 
antibody or another to potentially cure almost everything. In 
the end, the mode of action of mabs is sometimes not just 
compensatory, mimicking the action of a missing molecule 
– just as L-dopa or insulin –, or corrective, counterbalancing 
the action of another one – just as TKI, antibiotics or selec-
tive serotonin reuptake inhibitors. It may be transformative 
in the sense that it forces a mechanism to actually work in an 
entirely different way, one that is unnatural in a sense. So-
called superagonist mabs are an example: they bypass the 
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natural binding mechanism and some produce complex phe-
nomena of cross-linking (as was the case, with catastrophic 
consequences, for TGN1412 see Lemoine’s (2017). Whereas 
it is possible to predict whether, how strongly and how spe-
cifically mabs will bind to a given molecule drawing from 
traditional preclinical models, it would require sophisticated 
systems biology to predict the overall effect on human organ-
isms.
All of this makes mabs, by nature, a deposit of potential mag-
ic bullets: that they actually always work well is, of course, a 
different question. There is no doubt that some are extreme-
ly efficient. Trastuzumab (Herceptin) is the best known, and 
many others are resorted to in a wide variety of pathological 
conditions. But as antibodies, they also carry a risk of immu-
nogenicity that limits their efficiency in time. The major limit, 
however, is individual variability.
Indeed, this extreme specificity in binding logically involves 
that mabs are, in general, much more subjected to individual 
variability than other drugs. This is initially the reason why 
they much more often require companion tests and stratifi-
cation techniques, as compared to other drugs. This is also 
in response to the challenges raised by the development of 
mabs, that biobanks and complex algorithms based on sys-
tems biology have been developed, especially in cancer re-
search. 
All this shows that mabs involve most changes associated 
with ‘p-medicine’. None of these changes is uniquely theirs, 
some will possibly be developed further by other technologies 
legitimately associated with p-medicine. However, only mabs 
have so far involved all of them at the same time and thereby 
justify that these technologies may be associated in one pro-
ject, whatever ‘p-medicine’ should be called. Moreover, mabs 
have so far constituted the major part of successful innova-
tions in the last decade or two in medicine.
6 – Conclusion: The name and 
the thing   
Science often incorporates new words from common lan-
guage via analogy. ‘Personalized’ has been a buzzword since 
the early 2000s: cars, operating systems on computers, 
stamps, novels, mugs, T-shirts, educational plans, health 
plans and assessments of the evolution of prices have all been 
personalized. There is no technical sense in which the word 
is stipulated either in medicine or elsewhere, nor probably 
any unique specific sense. This is the reason why anyone, in 
medicine, may apply the term to what they are currently do-
ing and use it to emphasize any number of properties, from 
humane care to the use of molecular biomarkers, or whatever 
may, however remotely, share a property with anything else 
that can be called ‘personalized’. Of course, any other word 
emphasizing one of these same properties, yet with different 
connotations, as ‘precision’, may replace the original term 
because it more exactly describes what one wants to empha-
size. Then the same process may start again with this new 
term. A good example is the emergence of “precision psychi-
atry”. This term has been used to describe an ongoing pro-
ject, the “Research Domain Criteria” or RDoC project (Insel 
2014). This project involves neither different treatments, nor 
bypassing established disease entities through stratification, 
but the establishment of which modules dysfunction in men-
tal disorders, on the basis of which true disease entities, effi-
cient treatments, etc., may be used. Whereas the moleculari-
zation of disease entities had been achieved before precision 
medicine emerged, precision psychiatry is in part an agenda 
of molecularization of mental disorders. The analogy is thus 
quite strained. 
However, it is convenient for philosophers to suppose that 
there exists a clear sense in which the term is used, or even a 
prominent sense, or that there are real distinctions between 
‘precision’, ‘personalized’, ‘P4’, which it would be the job of 
philosophers par excellence to disentangle. It does not mean 
that all philosophers endorse this view (for a stark counterex-
ample see De Grandis and Halgunset’s [2016]), but it makes 
the traditional use of conceptual analysis easier, or even 
possible. The distinctions are there in the world, waiting for 
philosophers to make them clear and explicit. Often, claims 
about what personalized medicine ‘is’ conflict with what 
someone else thinks it really is (or should be). Obviously, 
such objections presupposed a meaning of personalization, 
based on whatever project or agenda the term may refer to, 
instead of considering the properties of this and other current 
treatments actually characterized as examples of ‘personal-
ized’ medicine. The current paper attempts to shift attention 
from the meaning and connotations of words to treatments 
actually introduced in clinical practice or under development.
Whatever p-medicine really is, we can agree that it is not 
classical medicine, vaguely defined as a set of more or less 
outdated technologies. This hardly would define what it is, 
even negatively, yet one is sometimes left with the impres-
sion— not in philosophical, but in scientific articles— that it 
is the only argument made. What it is not really, however, 
is one articulated agenda, the formulation of which could 
be found in editorials or even in a couple of programmatic 
papers (a point made by De Grandis and Halgunset [2016]). 
Such agendas are too anticipative to be assessable, too broad 
to be efficient, too many to be describable. What it really is, is, 
at its core, the actual, current development of a new class of 
treatments, monoclonal antibodies, characterized with many 
of the properties usually attributed to p-medicine: molecu-
lar approach, biomarkers, stratification, big data, systems 
biology, questioning received disease entities, few side ef-
fects, some dramatic successes, a lot of investment, hundreds 
of candidate molecules, and an unlimited field of potential 
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applications. By ‘really is’, I mean what has been achieved, 
not what we should consider it is ‘by nature.’ This is not an 
‘essence’ of p-medicine, i.e. something that is by definition 
‘precise’ or ‘personalized’, etc., but a fact that could have 
been interpreted and named otherwise. Around the core, the 
mantel is composed of less successful, or more localized, or 
more potential, technologies characterized by one, or some of 
these features, such as: clouds of data points about patients’ 
health without enough computer power or statistical power 
yet, much more specific drugs with a limited range of appli-
cations, genomic sequencing producing a surfeit of unused 
information. All this construction would have collapsed if it 
had not been for monoclonal antibodies. P-medicine is a mul-
tifaceted conceptual generalization of the many reasons why 
some monoclonal antibodies have been successful.
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